Healthy Eating Through Reduction Of Excess Sugar
NCT02948647 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 113
Last updated 2021-12-09
Summary
The purpose of the study is to determine the effect of dietary sugar reduction in obese children and examine whether there are differential effects based on genotype of a single amino acid substitution in the PNPLA3 gene that is highly prevalent in Hispanics and associated with significantly elevated liver fat.
Conditions
- NAFLD
Interventions
- OTHER
-
Standard of care plus sugar-reduction education
This is a 12-week intervention where subjects will be educated on how to monitor their added sugar consumption. They will be asked to eliminate consumption of sweetened beverages for the 12-week period and will be receiving a weekly delivery of water bottles to their homes to displace the sweetened beverages in their home environment.
Sponsors & Collaborators
-
Children's Hospital Los Angeles
collaborator OTHER -
University of Southern California
lead OTHER
Principal Investigators
-
Michael I Goran · University of Southern California; Children's Hospital Los Angeles
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- TRIPLE
- Model
- PARALLEL
Eligibility
- Min Age
- 12 Years
- Max Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2016-11-30
- Primary Completion
- 2020-11-30
- Completion
- 2021-11-30
Countries
- United States
Study Locations
More Related Trials
-
Pathogenesis of Pediatric Nonalcoholic Fatty Liver Disease (NAFLD)
NCT04634643 ·Status: RECRUITING
-
Effect of Vitamin E on Pediatric Nonalcoholic Fatty Liver Disease (NAFLD)
NCT00655018 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Expanded Access of Omegaven IV Fat Emulsion to Infants and Children With PNALD
NCT02929303 ·Status: APPROVED_FOR_MARKETING
-
Hepatoprotective Measures for Children at High Risk of NAFLD
NCT06918080 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE4
-
Glucomannan Effects on Children With Non-alcoholic Fatty Liver Disease
NCT01553500 ·Status: COMPLETED ·Phase: PHASE2
-
A Pilot Study of Acarbose as Treatment for Pediatric Non-alcoholic Fatty Liver Disease (NAFLD)
NCT00677521 ·Status: TERMINATED ·Phase: PHASE2
-
Impact of Soymilk on Liver Disease Severity of Children With Non-alcoholic Fatty Liver Disease (NAFLD)
NCT06133101 ·Status: RECRUITING ·Phase: PHASE2
-
Polyunsaturated Fatty Acids in Patients With NAFLD.
NCT02647294 ·Status: COMPLETED ·Phase: NA
-
Effects of Amino Acid Supplementation on Liver Lipid Content and Protein Metabolism in Obese Children
NCT02337894 ·Status: WITHDRAWN ·Phase: NA
-
Fatty Liver Disease in Obese Children
NCT02117700 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Low Dose Fat for the Prevention of Liver Disease in Babies With Gastrointestinal Disorders
NCT01373918 ·Status: TERMINATED ·Phase: PHASE4
-
Evaluating the Metabolic Effects of Polylactose: A Novel Prebiotic
NCT04100109 ·Status: WITHDRAWN ·Phase: NA
-
NAFLD Pediatric Database 2
NCT01061684 ·Status: COMPLETED
-
The Role of Microbiome Reprogramming on Liver Fat Accumulation
NCT03914495 ·Status: TERMINATED ·Phase: NA
-
Effects of Tomato Products in Children With NAFLD
NCT03463967 ·Status: UNKNOWN ·Phase: NA
-
Soluble Fibre Supplementation in NAFLD
NCT05480696 ·Status: RECRUITING ·Phase: PHASE2
-
Omegaven Treatment of Parenteral Nutrition (PN) Induced Liver Injury
NCT01089426 ·Status: COMPLETED ·Phase: NA
-
Hydroxytyrosol and Vitamin E in Pediatric NASH
NCT02842567 ·Status: COMPLETED ·Phase: PHASE3
-
Gemcabene for the Treatment of Pediatric NAFLD
NCT03436420 ·Status: TERMINATED ·Phase: PHASE2
-
SMOFlipid to Lessen the Severity of Neonatal Cholestasis
NCT02721277 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
SMOF Lipid for Children With Parenteral Nutrition Induced Liver Injury
NCT02412566 ·Status: APPROVED_FOR_MARKETING
-
Omegaven Protocol:Intermediate Size Patient Population
NCT03561194 ·Status: APPROVED_FOR_MARKETING
-
Omegaven® in the Treatment of Parenteral Nutrition (PN) Induced Liver Injury
NCT01845116 ·Status: COMPLETED ·Phase: PHASE2
-
Expanded Access Use of Omegaven® in the Treatment of Parenteral Nutrition Induced Liver Injury in Children
NCT02925520 ·Status: NO_LONGER_AVAILABLE
-
Treating Pediatric NAFLD with Nutrition
NCT05499585 ·Status: COMPLETED ·Phase: NA